^
    Back
    Association details:
    Biomarker:CLDN18.2 expression
    Cancer:Pancreatic Cancer
    Drug:ASP2138 (CD3 agonist, CLDN18.2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer

    Excerpt:
    ...Comparison of CLDN18.2 expression in baseline versus on-treatment tumor biopsies will be performed.`...
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    2962 / 9 - ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models

    Published date:
    03/15/2023
    Excerpt:
    ASP2138 showed cytotoxicity against CLDN18.2-expressing gastric or pancreatic cancer cells...SP2138 exhibited an antitumor effect on human CLDN18.2-expressing gastric cancer in a human PBMC-engrafted NOG mouse model in vivo. In summary, ASP2138 is expected to show a clinical effect through cytotoxicity against CLDN18.2-expressing tumor cells...